PF-05089771

PF-05089771
Legal status
Legal status	US: Investigational New Drug ;
Identifiers
	IUPAC name 4-[2-(3-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzene-1-sulfonamide;
CAS Number	1235403-62-9 ;
PubChem CID	46840946 ;
ChemSpider	29411106 ;
UNII	25U4N985O2 ;
ChEMBL	ChEMBL2325014 ;
CompTox Dashboard (EPA)	DTXSID301336085 ;
Chemical and physical data
Formula	C18H12Cl2FN5O3S2
Molar mass	500.34 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C1=CC(=C(C=C1Cl)C2=C(NN=C2)N)OC3=CC(=C(C=C3Cl)S(=O)(=O)NC4=CSC=N4)F;
	InChI InChI=1S/C18H12Cl2FN5O3S2/c19-9-1-2-14(10(3-9)11-6-24-25-18(11)22)29-15-5-13(21)16(4-12(15)20)31(27,28)26-17-7-30-8-23-17/h1-8,26H,(H3,22,24,25); Key:ZYSCOUXLBXGGIM-UHFFFAOYSA-N;

Last updated October 03, 2025

PF-05089771 is a selective, small-molecule Na_v1.7 and Na_v1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic.^[1]^[2]^[3] As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia.^[4]

References

↑ McMahon SB, Koltzenburg M, Tracey I, Turk D (March 2013). Wall & Melzack's Textbook of Pain. Elsevier Health Sciences. p. 508. ISBN 978-0-7020-5374-0.
↑ Martz L (June 2014). "Nav-i-gating antibodies for pain". SciBX: Science-Business EXchange. 7 (23): 662. doi: 10.1038/scibx.2014.662 .
↑ Alexandrou AJ, Brown AR, Chapman ML, Estacion M, Turner J, Mis MA, et al. (6 April 2016). "Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release". PLOS ONE. 11 (4) e0152405. Bibcode:2016PLoSO..1152405A. doi: 10.1371/journal.pone.0152405 . PMC 4822888 . PMID 27050761.
↑ Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–3699. doi: 10.1016/j.bmcl.2014.06.038 . PMID 25060923.

External links

"PF-05089771". AdisInsight. Springer Nature Switzerland AG.

This analgesic-related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] McMahon SB, Koltzenburg M, Tracey I, Turk D (March 2013). Wall & Melzack's Textbook of Pain. Elsevier Health Sciences. p. 508. ISBN 978-0-7020-5374-0.

[2] Martz L (June 2014). "Nav-i-gating antibodies for pain". SciBX: Science-Business EXchange. 7 (23): 662. doi: 10.1038/scibx.2014.662 .

[3] Alexandrou AJ, Brown AR, Chapman ML, Estacion M, Turner J, Mis MA, et al. (6 April 2016). "Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release". PLOS ONE. 11 (4) e0152405. Bibcode:2016PLoSO..1152405A. doi: 10.1371/journal.pone.0152405 . PMC 4822888 . PMID 27050761.

[4] Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–3699. doi: 10.1016/j.bmcl.2014.06.038 . PMID 25060923.

[1]

[2]

[3]

[4]

PF-05089771

Contents

See also

References

External links

Legal status

Legal status	US: Investigational New Drug
Identifiers
IUPAC name 4-[2-(3-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzene-1-sulfonamide
CAS Number	1235403-62-9
PubChem CID	46840946
ChemSpider	29411106
UNII	25U4N985O2
ChEMBL	ChEMBL2325014
CompTox Dashboard (EPA)	DTXSID301336085
Chemical and physical data
Formula	C₁₈H₁₂Cl₂FN₅O₃S₂
Molar mass	500.34 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1=CC(=C(C=C1Cl)C2=C(NN=C2)N)OC3=CC(=C(C=C3Cl)S(=O)(=O)NC4=CSC=N4)F
InChI InChI=1S/C18H12Cl2FN5O3S2/c19-9-1-2-14(10(3-9)11-6-24-25-18(11)22)29-15-5-13(21)16(4-12(15)20)31(27,28)26-17-7-30-8-23-17/h1-8,26H,(H3,22,24,25) Key:ZYSCOUXLBXGGIM-UHFFFAOYSA-N